Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Bio-Rad Laboratories, Inc.

NYSE: BIO · Industrial Applications and Services · 5 alerts · CIK 12208

Share price
$360.26Close, Nov 16
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Bio-Rad Laboratories, Inc. filings on SEC EDGAR ↗

10:59 AM ET Form 4
Insider Selling

Bio-Rad Laboratories EVP, General Counsel & Sec Courtney C. Enloe Sells $348K of Stock

Courtney C. Enloe, EVP, General Counsel & Sec, sold 902 shares of Bio-Rad Laboratories, Inc. at $386.17 a share, worth $348K in total on Nov 10, 2026. Shares held after the trade: 750 (-54.6%).

Value
$348K
Shares
902
Price
$386.17
Role
EVP, General Counsel & Sec
Holding change
-54.6%
Trade date
Nov 10, 2026
10:58 AM ET Form 4
Insider Selling

Bio-Rad Laboratories President & COO Jonathan P. DiVincenzo Sells $359K of Stock

Jonathan P. DiVincenzo, President & COO, sold 919 shares of Bio-Rad Laboratories, Inc. at $390.47 a share, worth $359K in total on Nov 9, 2026. Shares held after the trade: 1,962 (-31.9%).

Value
$359K
Shares
919
Price
$390.47
Role
President & COO
Holding change
-31.9%
Trade date
Nov 9, 2026
10:57 AM ET Form 4
Insider Selling

Bio-Rad Laboratories EVP, President, LSG James Barry Sells $540K of Stock

James Barry, EVP, President, LSG, sold 1,400 shares of Bio-Rad Laboratories, Inc. at $385.63 a share, worth $540K in total on Nov 9, 2026. Shares held after the trade: 625 (-69.1%).

Value
$540K
Shares
1,400
Price
$385.63
Role
EVP, President, LSG
Holding change
-69.1%
Trade date
Nov 9, 2026
4:20 PM ET 10-Q
Financial Results

Bio-Rad Laboratories Q3 2026 Results: Turns Profitable, Net Income $459M

Bio-Rad Laboratories reported net sales of $1,899.5 million for the first nine months of 2026, a slight increase from $1,890.0 million in 2025. Net income for the nine-month period rose significantly to $302.9 million compared to $39.9 million in the prior year, primarily driven by a $308.0 million gain from the change in fair market value of equity securities.

Key figure
Net income $459M
4:17 PM ET 8-K
Financial Results

Bio-Rad Laboratories Financial Results

Bio-Rad Laboratories reported third-quarter 2026 financial results with net sales of $656.4 million, representing a 0.7% increase on a currency-neutral basis. The company returned to growth driven by the Clinical Diagnostics segment and Droplet Digital PCR instruments, despite ongoing challenges in the academic research market. GAAP net income was significantly impacted by a change in the fair market value of the company's investment in Sartorius AG.

Term
Q3 2026

“Our third-quarter results reflect the steady progress we have been driving. We returned to currency-neutral revenue growth, led by Clinical Diagnostics and strong demand for our Droplet Digital™ PCR instruments. Excluding restructuring and impairment items, margins expanded, reflecting benefits of our transformation initiatives. The reprioritization of our R&D efforts is yielding new, differentiated products for our customers, and our progress gives us confidence in our 2026 outlook.”

Norman Schwartz, Bio-Rad’s Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.